Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulacimstat in post-MI left-ventricular dysfunction
NCT02452515Phase 2Completed
- Sponsor
- Bayer
- Start
- Jul 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, single-blind trial of fulacimstat in left ventricular dysfunction (4 arms), sponsored by Bayer. Primary endpoints: Number of participants with adverse events at 20 days and Number of participants with serious adverse events at 20 days. Started Jul 2015; status: completed.
02
Drugs
fulacimstat
03
Conditions
left ventricular dysfunction
Beyond the preview
Go deeper on NCT02452515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452515.